Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (ABUS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
3.19 -0.02 (-0.62%) 04/22/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 3.19 unch (unch) 16:03 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.14
Day High
3.27
Open 3.25
Previous Close 3.21 3.21
Volume 652,900 652,900
Avg Vol 1,279,910 1,279,910
Stochastic %K 53.11% 53.11%
Weighted Alpha +5.13 +5.13
5-Day Change -0.09 (-2.74%) -0.09 (-2.74%)
52-Week Range 2.63 - 4.72 2.63 - 4.72
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 614,651
  • Shares Outstanding, K 191,480
  • Annual Sales, $ 6,170 K
  • Annual Income, $ -69,920 K
  • EBIT $ -76 M
  • EBITDA $ -75 M
  • 60-Month Beta 1.45
  • Price/Sales 97.74
  • Price/Cash Flow N/A
  • Price/Book 6.15

Options Overview Details

View History
  • Implied Volatility 77.26% ( -90.50%)
  • Historical Volatility 58.56%
  • IV Percentile 76%
  • IV Rank 14.23%
  • IV High 443.77% on 08/05/24
  • IV Low 16.46% on 05/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 887
  • Volume Avg (30-Day) 781
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 29,356
  • Open Int (30-Day) 28,069

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +18.15%
on 04/09/25
Period Open: 3.28
3.61 -11.63%
on 04/02/25
-0.09 (-2.74%)
since 03/21/25
3-Month
2.70 +18.15%
on 04/09/25
Period Open: 3.22
3.70 -13.78%
on 02/25/25
-0.03 (-0.93%)
since 01/22/25
52-Week
2.63 +21.29%
on 05/02/24
Period Open: 2.64
4.72 -32.49%
on 09/09/24
+0.55 (+20.83%)
since 04/22/24

Most Recent Stories

More News
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

ABUS : 3.19 (-0.62%)
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS : 3.19 (-0.62%)
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

ABUS : 3.19 (-0.62%)
Arbutus Provides 2025 Corporate and Financial Update

ABUS : 3.19 (-0.62%)
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

ABUS : 3.19 (-0.62%)
Arbutus Biopharma Reports 50% Functional Cure Rate in Phase 2a Clinical Trial for Chronic Hepatitis B Virus

Arbutus Biopharma reports 50% functional cure rate in HBeAg-negative patients with low HBsAg after IM-PROVE I trial.Quiver AI SummaryArbutus Biopharma Corporation announced promising results from its IM-PROVE...

ABUS : 3.19 (-0.62%)
Arbutus Biopharma and Barinthus Bio Report Encouraging Preliminary Results from Phase 2a IM-PROVE II Clinical Trial for Chronic Hepatitis B Virus

Imdusiran, VTP-300, and low-dose nivolumab demonstrated significant HBsAg reduction in a Phase 2a clinical trial for chronic hepatitis B.Quiver AI SummaryArbutus Biopharma and Barinthus Biotherapeutics...

ABUS : 3.19 (-0.62%)
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

ABUS : 3.19 (-0.62%)
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

ABUS : 3.19 (-0.62%)
Arbutus to Present at Jefferies London Healthcare Conference

ABUS : 3.19 (-0.62%)
What To Expect From Petco’s (WOOF) Q4 Earnings

What To Expect From Petco’s (WOOF) Q4 Earnings

EYE : 11.48 (+4.36%)
WOOF : 3.11 (+0.65%)
CRMT : 48.02 (+3.45%)
Petco Stock Falls Ahead Of Q4 Earnings But Retail Stays Bullish

Sentiment on Stocktwits inched up in the bullish zone on Friday

WOOF : 3.11 (+0.65%)
VTI : 259.03 (+2.55%)
VB : 207.66 (+2.66%)
1 High-Flying Stock with Exciting Potential and 2 to Ignore

1 High-Flying Stock with Exciting Potential and 2 to Ignore

WOOF : 3.11 (+0.65%)
LYV : 128.50 (+4.07%)
CMG : 47.10 (+1.23%)
1 Consumer Stock to Buy in 2025 and 2 to Snub

1 Consumer Stock to Buy in 2025 and 2 to Snub

JWN : 24.06 (+1.05%)
ORLY : 1,393.54 (+1.83%)
WOOF : 3.11 (+0.65%)
Petco Stock Surges On Leadership Hires: Retail Stays Bullish

Petco named Sabrina Simmons, former CFO at Gap as its finance chief.

WOOF : 3.11 (+0.65%)
VTI : 259.03 (+2.55%)
VB : 207.66 (+2.66%)
3 Reasons to Avoid WOOF and 1 Stock to Buy Instead

3 Reasons to Avoid WOOF and 1 Stock to Buy Instead

MELI : 2,128.33 (+3.50%)
WOOF : 3.11 (+0.65%)
Specialty Retail Stocks Q3 Results: Benchmarking Petco (NASDAQ:WOOF)

Specialty Retail Stocks Q3 Results: Benchmarking Petco (NASDAQ:WOOF)

EYE : 11.48 (+4.36%)
LESL : 0.6200 (+8.07%)
WOOF : 3.11 (+0.65%)
TSCO : 50.28 (+1.39%)
Q3 Earnings Recap: National Vision (NASDAQ:EYE) Tops Specialty Retail Stocks

Q3 Earnings Recap: National Vision (NASDAQ:EYE) Tops Specialty Retail Stocks

EYE : 11.48 (+4.36%)
LESL : 0.6200 (+8.07%)
WOOF : 3.11 (+0.65%)
TSCO : 50.28 (+1.39%)
Do Options Traders Know Something About Petco Health (WOOF) Stock We Don't?

Investors in Petco Health and Wellness Company, Inc. WOOF need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 17, 2025 $30.00 Put had some of...

WOOF : 3.11 (+0.65%)
Q3 Earnings Highlights: Leslie's (NASDAQ:LESL) Vs The Rest Of The Specialty Retail Stocks

Q3 Earnings Highlights: Leslie's (NASDAQ:LESL) Vs The Rest Of The Specialty Retail Stocks

EYE : 11.48 (+4.36%)
LESL : 0.6200 (+8.07%)
WOOF : 3.11 (+0.65%)
TSCO : 50.28 (+1.39%)
What To Expect From Petco’s (WOOF) Q4 Earnings

What To Expect From Petco’s (WOOF) Q4 Earnings

EYE : 11.48 (+4.36%)
WOOF : 3.11 (+0.65%)
CRMT : 48.02 (+3.45%)
Petco Stock Falls Ahead Of Q4 Earnings But Retail Stays Bullish

Sentiment on Stocktwits inched up in the bullish zone on Friday

WOOF : 3.11 (+0.65%)
VTI : 259.03 (+2.55%)
VB : 207.66 (+2.66%)
1 High-Flying Stock with Exciting Potential and 2 to Ignore

1 High-Flying Stock with Exciting Potential and 2 to Ignore

WOOF : 3.11 (+0.65%)
LYV : 128.50 (+4.07%)
CMG : 47.10 (+1.23%)
1 Consumer Stock to Buy in 2025 and 2 to Snub

1 Consumer Stock to Buy in 2025 and 2 to Snub

JWN : 24.06 (+1.05%)
ORLY : 1,393.54 (+1.83%)
WOOF : 3.11 (+0.65%)
Petco Stock Surges On Leadership Hires: Retail Stays Bullish

Petco named Sabrina Simmons, former CFO at Gap as its finance chief.

WOOF : 3.11 (+0.65%)
VTI : 259.03 (+2.55%)
VB : 207.66 (+2.66%)
3 Reasons to Avoid WOOF and 1 Stock to Buy Instead

3 Reasons to Avoid WOOF and 1 Stock to Buy Instead

MELI : 2,128.33 (+3.50%)
WOOF : 3.11 (+0.65%)
Specialty Retail Stocks Q3 Results: Benchmarking Petco (NASDAQ:WOOF)

Specialty Retail Stocks Q3 Results: Benchmarking Petco (NASDAQ:WOOF)

EYE : 11.48 (+4.36%)
LESL : 0.6200 (+8.07%)
WOOF : 3.11 (+0.65%)
TSCO : 50.28 (+1.39%)
Q3 Earnings Recap: National Vision (NASDAQ:EYE) Tops Specialty Retail Stocks

Q3 Earnings Recap: National Vision (NASDAQ:EYE) Tops Specialty Retail Stocks

EYE : 11.48 (+4.36%)
LESL : 0.6200 (+8.07%)
WOOF : 3.11 (+0.65%)
TSCO : 50.28 (+1.39%)
Do Options Traders Know Something About Petco Health (WOOF) Stock We Don't?

Investors in Petco Health and Wellness Company, Inc. WOOF need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 17, 2025 $30.00 Put had some of...

WOOF : 3.11 (+0.65%)
Q3 Earnings Highlights: Leslie's (NASDAQ:LESL) Vs The Rest Of The Specialty Retail Stocks

Q3 Earnings Highlights: Leslie's (NASDAQ:LESL) Vs The Rest Of The Specialty Retail Stocks

EYE : 11.48 (+4.36%)
LESL : 0.6200 (+8.07%)
WOOF : 3.11 (+0.65%)
TSCO : 50.28 (+1.39%)

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 3.40
2nd Resistance Point 3.33
1st Resistance Point 3.26
Last Price 3.19
1st Support Level 3.13
2nd Support Level 3.06
3rd Support Level 2.99

See More

52-Week High 4.72
Fibonacci 61.8% 3.92
Fibonacci 50% 3.68
Fibonacci 38.2% 3.43
Last Price 3.19
52-Week Low 2.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.